These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32366840)

  • 1. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer.
    Wang G; Wang Q; Liang N; Xue H; Yang T; Chen X; Qiu Z; Zeng C; Sun T; Yuan W; Liu C; Chen Z; He X
    Cell Death Dis; 2020 May; 11(5):313. PubMed ID: 32366840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
    Özdemir BH
    Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
    Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
    Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Xu RC; Wang F; Sun JL; Abuduwaili W; Zhang GC; Liu ZY; Liu TT; Dong L; Shen XZ; Zhu JM
    J Transl Med; 2022 Dec; 20(1):579. PubMed ID: 36494846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
    Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
    World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
    Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
    Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
    Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
    Gurzu S; Szodorai R; Jung I; Banias L
    J Cancer Res Clin Oncol; 2024 May; 150(5):270. PubMed ID: 38780656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.
    Matter MS; Marquardt JU; Andersen JB; Quintavalle C; Korokhov N; Stauffer JK; Kaji K; Decaens T; Quagliata L; Elloumi F; Hoang T; Molinolo A; Conner EA; Weber A; Heikenwalder M; Factor VM; Thorgeirsson SS
    Hepatology; 2016 Jun; 63(6):1888-99. PubMed ID: 26844528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necroptosis microenvironment directs lineage commitment in liver cancer.
    Seehawer M; Heinzmann F; D'Artista L; Harbig J; Roux PF; Hoenicke L; Dang H; Klotz S; Robinson L; Doré G; Rozenblum N; Kang TW; Chawla R; Buch T; Vucur M; Roth M; Zuber J; Luedde T; Sipos B; Longerich T; Heikenwälder M; Wang XW; Bischof O; Zender L
    Nature; 2018 Oct; 562(7725):69-75. PubMed ID: 30209397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
    Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
    J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
    Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
    Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Look into hepatic progenitor cell associated trait: Histological heterogeneity of hepatitis B-related combined hepatocellular-cholangiocarcinoma.
    Cai X; Xiong J; Hu QG; Zhao QD; Wu D; Tang LG; Wan CD; Wei LX
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):873-879. PubMed ID: 29270746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
    Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
    Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.
    Bergquist JR; Groeschl RT; Ivanics T; Shubert CR; Habermann EB; Kendrick ML; Farnell MB; Nagorney DM; Truty MJ; Smoot RL
    HPB (Oxford); 2016 Nov; 18(11):886-892. PubMed ID: 27546172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.
    Sekiya S; Suzuki A
    J Clin Invest; 2012 Nov; 122(11):3914-8. PubMed ID: 23023701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.